findmyKOL

Stephen Ansell, MD, PhD

Enriched profile

Professor of Medicine, Mayo Clinic College of Medicine and Science; Chair, Division of Hematology; Chair, Lymphoma Disease Group; Dorotha W. and Grant L. Sundquist Professor in Hematologic Malignancies Research; Consultant, Division of Hematology, Mayo Clinic · Mayo Clinic

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Rochester, MN · Midwest · United StatesSpecialtyHematologyFocusLymphoma Diagnosis and Treatment+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2022–2024NIH funding2002–2024

Stephen Ansell is Professor of Medicine, Mayo Clinic College of Medicine and Science; Chair, Division of Hematology; Chair, Lymphoma Disease Group; Dorotha W. and Grant L. Sundquist Professor in Hematologic Malignancies Research; Consultant, Division of Hematology, Mayo Clinic at Mayo Clinic. OpenAlex indexes 1,478 publications with 52,585 citations (h-index 113); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory. Clarivate lists Stephen Ansell as a Highly Cited Researcher (Clinical Medicine, 2020-2021).

Data verified 17 Oct 2026

Overview

Updated 18 Oct 2026

Stephen Ansell, M.D., is Professor of Medicine, Mayo Clinic College of Medicine and Science. The public record shows 1,478 publications with 52,585 citations (h-index 113), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 2 companies, 4 NIH-funded awards (2002–2024).

  • Most recent indexed publication: 2026 · British journal of haematology
  • Top research focus: Lymphoma Diagnosis and Treatment
  • 10 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 2 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma10 trialsHodgkin Disease4 trialsLymphoma, B-Cell4 trialsLymphoma, Non-Hodgkin3 trialsLymphoma, Follicular3 trialsLeukemia (AML/ALL/CML/CLL)2 trialsInflammation2 trialsLymphoma, Large B-Cell, Diffuse2 trialsBurkitt Lymphoma2 trialsGranuloma2 trialsLymphomatoid Granulomatosis2 trialsLeukemia, Lymphocytic, Chronic, B-Cell2 trialsLymphoma, B-Cell, Marginal Zone2 trialsUlcer1 trialLymphoma, Primary Effusion1 trialPlasmablastic Lymphoma1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialWaldenstrom Macroglobulinemia1 trialLeukemia, Hairy Cell1 trialIntraocular Lymphoma1 trialLeukemia, Lymphoid1 trialST Elevation Myocardial Infarction1 trialMycosis Fungoides1 trialLymphoma, T-Cell, Peripheral1 trialLymphoma, T-Cell1 trialBlastic Plasmacytoid Dendritic Cell Neoplasm1 trialEnteropathy-Associated T-Cell Lymphoma1 trialLeukemia, T-Cell1 trial

Research focus

OpenAlex concept fingerprint
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchCancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Drugs & molecules

across trials, industry payments and publications
Adcetrisgeneric · Brentuximab vedotinClinical trials—Industry payments5Publications7NivolumabClinical trials2Industry payments—Publications6RituximabClinical trials4Industry payments—Publications1IpilimumabClinical trials1Industry payments—Publications2PembrolizumabClinical trials1Industry payments—Publications2TemsirolimusClinical trials2Industry payments—Publications1Interleukin-12Clinical trials2Industry payments—Publications—Arm A: RituximabClinical trials1Industry payments—Publications—Arm B: GA101Clinical trials1Industry payments—Publications—Denileukin diftitoxClinical trials1Industry payments—Publications—MaplirpaceptClinical trials1Industry payments—Publications—OntorpaceptClinical trials1Industry payments—Publications—

Works with

trial sponsors and companies reporting payments
AstraZeneca Pharmaceuticals LPClinical trials—Industry payments6National Cancer Institute (NCI)Clinical trials5Industry payments—Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments5Mayo ClinicClinical trials3Industry payments—Alliance for Clinical Trials in OncologyClinical trials1Industry payments—PrECOG, LLC.Clinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,478publications

Distinct works indexed by OpenAlex, matched via ORCID; 82 in PubMed.

52,585citations

Total citations across indexed works.

113h-index

Hirsch index (OpenAlex). i10-index 541.

Clinical & industry

trials, payments and federal funding
10clinical trials

Investigator role on registered studies.

View trials ↓
2companies · 2022–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 2002–2024

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 18 Oct 2026

2 companies reported payments to CMS in program years 2022–2024. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    98.7%
    Other drugs affecting bone structure and mineralization98.7%
    Romosozumab-aqqg100%
    Part B, office-administered≥11 patients
  • Dermatology

    0.8%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.8%
    Acyclovir100%
    Part D<11 patients
  • Blood & clotting

    0.5%
    Other systemic hemostatics0.5%
    Doptelet100%
    Part D<11 patients
Where care is delivered (Part B)1.6% facility · 98.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 18 Oct 2026

4 NIH research awards on record, funded 2002–2024 per NIH RePORTER. The latest:

Publications

Updated 18 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 18 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Thomas E. Witzig420Thomas M. Habermann384Anne J. Novak323Patrick B. Johnston288David J. Inwards264Grzegorz S. Nowakowski263James R. Cerhan253Jonas Paludo250Ivana N. Micallef245Luis F. Porrata218Matthew J. Maurer217Morie A. Gertz197José C. Villasboas194Brian K. Link155Yucai Wang143Prashant Kapoor140Zhi-Zhang Yang138Andrew L. Feldman136Carrie A. Thompson135Patrizia Mondello123Shaji Kumar122Yi Lin121Susan L. Slager119Robert A. Kyle117Angela Dispenzieri111Kerstin Wenzl111Jithma P. Abeykoon109N. Nora Bennani109Craig B. Reeder107Rebecca L. King99Svetomir N. Markovic99Arushi Khurana93Jordan E. Krull91William R. Macon91Martha Q. Lacy91Ranjana H. Advani90Michelle K. Manske89David Dingli85Sikander Ailawadhi82Brad S. Kahl82

Online presence

Updated 18 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/stephen-ansell-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/mayo-clinic_the-american-society-of-hematology-recognizes-activity-6882437883878232064-51bN

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • Other

    mayoclinic.elsevierpure.com/en/persons/stephen-maxted-ansell

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.elsevierpure.com ↗
  • Other

    mayoclinic.org/biographies/ansell-stephen-m-m-d-ph-d/bio-20053059

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD (M.B., Ch.B.)

    University of Pretoria, South Africa

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aol.amegroups.org ↗
  • PhD

    University of Pretoria, South Africa

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aol.amegroups.org ↗
  • Board Certified

    American Board of Internal Medicine, Hematology and Medical Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗

Editorial & leadership roles

journal and society appointments
  • Chair

    Division of Hematology, Mayo Clinic

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
  • Chair

    Lymphoma Disease/Group, Mayo Clinic

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗
  • Co-leader

    Hematological Malignancies Program, Mayo Clinic Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aol.amegroups.org ↗

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Guest

    Mayo Clinic Talks podcast, episode 'Hodgkin's Lymphoma'

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
  • Guest

    Mayo Clinic Talks podcast, episode 'Non-Hodgkin's Lymphoma'

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
  • Video interview subject

    VJHemOnc, discusses B-cell malignancy biology and the tumor microenvironment

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
  • Video interview

    Healio, discusses circulating tumor DNA (ctDNA) research presented at ASH Annual Meeting

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗
  • Featured profile

    'Meet the investigator: Stephen M. Ansell, M.D., Ph.D.', Mayo Clinic Comprehensive Cancer Center Blog

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerblog.mayoclinic.org ↗
  • Profile feature

    'Stephen M. Ansell, MD, PhD: Translational scientist at heart', Healio

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.